TachoSil® Versus Surgicel® Original for the Secondary Treatment of Local Bleeding in Adult and Pediatric Patients Undergoing Hepatic Resection Surgery

Completed · Phase 3

Conditions studied: Hemorrhage

In brief

The efficacy and safety of TachoSil® as secondary hemostatic treatment in hepatic resection surgery will be compared to the standard USA licensed hemostatic agent, Surgicel® Original. Hemostatic efficacy will be evaluated intraoperatively after application of randomized treatment.

Key facts

Study ID

NCT01192022

Run by

Takeda

People needed

253

Starts

2010-08-01

Expected to finish

2013-05-01

Last updated by the study team

2015-11-25

Who can join

Age: any. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Resection of at least the equivalent tissue volume of 1 anatomical segment of the liver
• Minor to moderate (oozing/diffuse) bleeding from the resection area persisting after conventional resection procedure and primary control of arterial pulsating bleeding or major venous hemorrhage by sutures, ligations, clips, vascular stapler, point electrocautery or focal radiofrequency ablation
• Need for additional supportive hemostatic treatment
• Expected ability to lightly press the trial treatment to the liver resection wound for 3 minutes

You may not qualify if…

• Indication for emergency surgery
• Known coagulopathy (as judged relevant by the investigator)
• Known or suspected hypersensitivity to any ingredient of the investigational medicinal products (e.g. human fibrinogen, human thrombin and/or collagen of any origin)
• Patient unwilling to receive blood products
• Known current alcohol or drug abuse
• Pregnancy, breastfeeding, no use of acceptable contraceptive method in females of childbearing potential
• Dry surgical field of the targeted application area
• Occurrence of any serious surgical complication
• Disseminated intravascular coagulopathy (DIC), i.e. microvascular bleeding
• Application of topical hemostatic material on the liver resection wound
• Radiofrequency precoagulation of the liver resection wound except focal radiofrequency ablation of vessels as primary hemostatic treatment

Where it is running

• Study site — Los Angeles, California, United States
• Study site — Washington D.C., District of Columbia, United States
• Study site — Chicago, Illinois, United States
• Study site — Louisville, Kentucky, United States
• Study site — New Orleans, Louisiana, United States
• Study site — Burlington, Massachusetts, United States
• Study site — St Louis, Missouri, United States
• Study site — Newark, New Jersey, United States
• Study site — New York, New York, United States
• Study site — Charlotte, North Carolina, United States
• Study site — Cincinnati, Ohio, United States
• Study site — Philadelphia, Pennsylvania, United States
• Study site — Charleston, South Carolina, United States
• Study site — Memphis, Tennessee, United States
• Study site — Nashville, Tennessee, United States
• Study site — Charlottesville, Virginia, United States
• Study site — Madison, Wisconsin, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.